Top 10 Healthcare Companies by Revenue in 2025

By Editorial Team -
Here are the top 10 healthcare companies by revenue as of 2024-2025, primarily based on trailing twelve-month (TTM) and fiscal year 2024 revenue data from multiple sources:
Top 10 Healthcare Companies by Revenue

1. UnitedHealth Group Inc.
  • Revenue: Approximately $379.5 billion to $410 billion
  • Description: A leading health insurance company providing data analytics, consulting, and pharmacy care services.
  • Market: NYSE, USA (1, 2, 4)
2. CVS Health Corp.
  • Revenue: Around $361 billion to $373 billion
  • Description: A major pharmacy benefits manager and health services provider.
  • Market: NYSE, USA (1, 2, 4)
3. McKesson Corp.
  • Revenue: About $309 billion to $359 billion
  • Description: A global pharmaceutical distribution and healthcare services company.
  • Market: NYSE, USA (1, 2, 4)
4. Cencora (formerly AmerisourceBergen)
  • Revenue: Approximately $294 billion to $310 billion
  • Description: A pharmaceutical sourcing and distribution services company.
  • Market: NYSE, USA (2, 4)
5. Cardinal Health Inc.
  • Revenue: Around $220 billion to $227 billion
  • Description: Manufacturer and distributor of medical and laboratory products serving hospitals and clinics.
  • Market: NYSE, USA (1, 4)
6. Cigna Group
  • Revenue: About $204 billion to $247 billion
  • Description: Global health services company with clinics and healthcare facilities in over 30 countries.
  • Market: NYSE, USA (1, 4)
7. Elevance Health (formerly Anthem)
  • Revenue: Approximately $172 billion to $177 billion
  • Description: Offers health plans and clinical, behavioral, pharmacy, and complex-care products.
  • Market: NYSE, USA (1, 4)
8. Johnson & Johnson
  • 2024 revenue: $88.8 billion
  • 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion
  • Headquarters: New Brunswick, New Jersey
  • Johnson & Johnson has seen significant change in recent years, first with its consumer healthcare separation in the summer of 2023 and more recently with Stelara’s loss of exclusivity at the start of 2025. Through these developments—and even more now in the wake of them—the company has remained focused on its innovative drug business. Thanks to new approvals and future label expansions, the company has projected that its innovative medicines business can deliver annual growth of 5% to 7% from 2025 to 2030. Of J&J’s $88.8 billion in global sales last year, its innovative medicines group delivered annual sales of nearly $57 billion. Its medtech division, meanwhile, pulled down nearly $32 billion. Both groups delivered sales growth of 4% to 5% compared with 2023.
Related: Top 10 drugs losing US exclusivity in 2025

9. Roche
  • 2024 revenue: USD $73.6 billion (60.5 billion Swiss francs)
  • 2025 First-Quarter reported sales growth of 6% to USD $18.7 Billion (CHF 15.4 billion)
  • Headquarters: Basel, Switzerland
  • If one were to name 2024’s star pharmaceutical products beyond the GLP-1s, Roche’s eye injection Vabysmo would likely be on the list. First approved by the FDA in January 2022 as a competitor to Bayer and Regeneron’s Eylea, Vabysmo already reached 3.86 billion Swiss francs (about $4.5 billion) of sales in 2024. The rise of Vabysmo pushed the checkpoint inhibitor Tecentriq off Roche’s top three medicines list by sales.
10. Sinopharm Group
  • 2024 revenue: USD $80 billion.
  • 2025 First-Quarter reported sales: USD $19 billion (CNY $141 B)
  • Market Cap: $7.37 B (USD)
  • Price-to-Sales (P/S) ratio: 7.37/73.9 = 0.1*
  • Sinopharm reported 2024 revenue of approximately $80 billion USD, ranking it second among the top pharmaceutical companies by revenue. However, its market capitalization stands at only about $7.37 billion USD, classifying it as a relatively small-cap company and indicating it is significantly undervalued based on its Price-to-Sales (P/S) ratio of roughly 0.1. This discrepancy suggests that Sinopharm’s stock price does not fully reflect its revenue-generating capacity, potentially due to market perceptions, regional factors, or other risks affecting investor confidence.
  • Full Name: Sinopharm Group Co., Ltd.
  • Listed on the Hong Kong Stock Exchange (HKEX) - Stock Code: 1099.HK

Disclaimer

The information presented in this article, "Top 10 Healthcare Companies by Revenue in 2025," is intended for general informational purposes only and should not be construed as professional financial, investment, or medical advice. The revenue figures, company rankings, and projections are based on publicly available data, company reports, and industry estimates as of 2025. All currency conversions, where applicable, are based on annual average exchange rates, and revenues outside the health sciences sector have been excluded for consistency1.

While efforts have been made to ensure the accuracy and timeliness of the information, One Day Advisor and the article’s authors do not guarantee the completeness, reliability, or suitability of the content for any particular purpose. Readers are encouraged to verify details independently and consult qualified professionals before making any business, investment, or healthcare decisions based on the information provided.

The article may reference ongoing developments, regulatory actions, or market events that are subject to change. One Day Advisor is not responsible for any losses or damages arising from the use of this information.


Related:


Top 10 Pharmaceutical Companies by Revenue in 2025

Top 10 Drugs by Worldwide Sales in 2025

Comments

Post a Comment

Pages

Popular posts from this blog

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025

By Editorial Team -
Image
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching ...
Read more

Top 10 Most Anticipated Drug Launches of 2025

By Editorial Team -
Image
Biopharma may soon be in for a blockbuster boom. In the latest edition of its annual ranking of the biggest potential drug launches of the coming year, Evaluate listed 10 drugs that are slated to earn approvals in 2025. According to the analysts’ forecasts, all together, the meds stand to generate a whopping $29 billion in annual sales by the end of the decade. That’s nearly double the estimate for last year’s top 10 . In that case, Evaluate calculated a conservative $15.2 billion in 2028 sales for 2024’s biggest expected launches, which included the likes of Bristol Myers Squibb’s schizophrenia drug Cobenfy , Eli Lilly’s Alzheimer’s disease med Kisunla and Madrigal Pharmaceuticals’ MASH treatment Rezdiffra in the top three—all of which were indeed approved throughout last year. In fact, 2025’s total is the highest in the last five years, topping even Evaluate’s high-flying forecast for 2022, when the analysts estimated total 2026 sales of $26.9 billion for the year’s  most anti...
Read more

Top 10 Pharma Companies by Market Cap in 2025

By Editorial Team -
Image
Here are the top 10 pharmaceutical companies by market cap as of July 2025. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com Lilly—boosted by...
Read more

Top 10 Drugs Losing US Exclusivity in 2025

By Editorial Team -
Image
Summary 1. Stelara: 2024 U.S. sales: $6.72 billion 2. Eylea: 2024 U.S. sales: $4.77 billion 3. Prolia/Xgeva: 2024 U.S. sales: $4.39 billion 4. Entresto: 2024 U.S. sales: $4.05 billion 5. Soliris: 2024 U.S. sales: $1.52 billion 6. Promacta: 2024 U.S. sales: $1.18 billion 7. Simponi/Simponi Aria: 2024 U.S. sales: $1.08 billion 8. Tysabri: 2024 U.S. sales: $920 million 9. Tasigna: 2024 U.S. sales: $848 million 10. Brilinta: 2024 U.S. sales: $751 million Introduction While the pharmaceutical industry routinely faces high-profile losses of exclusivity each year, this year's list is particularly notable. Johnson & Johnson’s Stelara is already contending with several biosimilars, with more expected throughout the year. With $6.72 billion in U.S. sales projected for 2024, Stelara represents the largest U.S. loss of exclusivity since AbbVie’s Humira patent cliff in early 2023. Although Johnson & Johnson had anticipated a “late 2023” patent expiration, the company extended Stelara’s ...
Read more

Glutathione vs NAD: What's the Difference?

By Editorial Team -
Image
What's the difference between glutathione and NAD? We will cover the essentials and explain about each of these nutrients below.  What is Glutathione? Glutathione or GSH (tripeptide of glutamic acid, cysteine, and glycine) is referred to as the body’s “master antioxidant” or the “mother of all antioxidants” because it is your body’s primary and most prevalent protector, found in all mammalian tissue. Types of Glutathione There is a lot of confusion about GSH and what makes an effective glutathione supplement. There are different types, different formulas, and a lot of different companies saying different things. L-Glutathione or Reduced Glutathione because it is the most commonly found, least expensive, and the true core behind other forms you will find. There is some debate whether L-Glutathione alone can be effective taken orally. The theory being the enzymes in your stomach break it down before it can ever reach the blood stream and become useful. Some  evidence ...
Read more

Top 10 Pharma Companies by R&D Spend 2024

By Editorial Team -
Image
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ​( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Read more

7 Best Crypto Exchanges Malaysia 2025

By Editorial Team -
Image
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Read more

5 Top Silver ETFs 2025: What You Need to Know

By Editorial Team -
Image
Along with gold, silver is in high demand as precious metals are highly sought after as safe havens in uncertain economic environments, boosting prices and assets for top silver ETFs like the iShares Silver Trust (SLV). Investors use silver ETFs for various purposes. Other than its safe-haven benefits, some invest for speculative reasons, hoping to profit from potential increases in silver prices or as a hedge against geopolitical turmoil or currency devaluation. Keep reading to learn more about investing in silver and see a list of top ETFs investing in the precious metal.   What Are Silver ETFs?  Silver ETFs are exchange-traded funds that provide exposure to the price of silver, a precious metal. These ETFs are designed to track the performance of silver prices, making it easier for investors to gain exposure to the silver market without physically owning and storing the metal itself. Silver's unique combination of properties, including its electrical conductivity, thermal c...
Read more